Literature DB >> 8280718

Possible myocardial toxicity associated with interleukin-4 therapy.

E G Trehu1, J M Isner, J W Mier, D D Karp, M B Atkins.   

Abstract

Interleukin (IL)-4 is a cytokine produced by T lymphocytes, which may play a role in allergic inflammatory processes through its stimulatory effects on immunoglobulin E production and mast cells. In this report, we describe a patient with metastatic melanoma involving the heart who had biopsy-proven myocarditis after treatment with high-dose IL-4. Because of the uncharacteristic predominance of polymorphonuclear and mast cells in the inflammatory infiltrate of this patient's myocardium, we postulate a unique mechanism of IL-4-associated myocarditis. Three other patients treated with IL-4 had less well-defined cardiac abnormalities, suggesting that patients receiving IL-4 may be at risk for cardiac toxicity. Additional studies will be necessary to confirm such an association.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280718     DOI: 10.1097/00002371-199311000-00015

Source DB:  PubMed          Journal:  J Immunother Emphasis Tumor Immunol        ISSN: 1067-5582


  2 in total

Review 1.  Clinical toxicity of cytokines used as haemopoietic growth factors.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

2.  Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E5Y92).

Authors:  Peter H Wiernik; Janice P Dutcher; Xiapan Yao; Usha Venkatraj; Carla I Falkson; Jacob M Rowe; Peter A Cassileth
Journal:  J Immunother       Date:  2010 Nov-Dec       Impact factor: 4.456

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.